产品说明书
Bardoxolone
 |
同义名 : | 齐墩果烷三萜化合物 ;CDDO;RTA 401 |
| CAS号 : | 218600-44-3 | |
| 货号 : | A165469 | |
| 分子式 : | C31H41NO4 | |
| 纯度 : | 99%+ | |
| 分子量 : | 491.662 | |
| MDL号 : | MFCD07772296 | |
| 存储条件： |
粉末 Sealed in dry,Store in freezer, under -20°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(213.56 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Bardoxolone (CDDO) serves as a novel activator of the nuclear regulatory factor (Nrf-2), particularly beneficial for studying chronic kidney disease. Additionally, Bardoxolone acts as a potent inhibitor of necroptosis induced by Z-VAD-FMK[1]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00529113 | Pancreatic Neoplasms ... 展开 >> Pancreatic Cancer 收起 << | Phase 1 Phase 2 | Terminated(To pursue other ind... 展开 >>ications) 收起 << | - | United States, Colorado ... 展开 >> Rocky Mountain Cancer Center (US Oncology) Denver, Colorado, United States United States, Florida Cancer Centers of Florida (US Oncology) Ocoee, Florida, United States United States, Indiana Central Indiana Cancer Centers (US Oncology) Indianapolis, Indiana, United States United States, Texas Sammons Cancer Center (US Oncology) Dallas, Texas, United States, 75246 United States, Washington Northwest Cancer Specialist- Vancouver Cancer Specialist (US Oncology) Vancouver, Washington, United States 收起 << |
| NCT01500798 | Chronic Kidney Disease ... 展开 >> Type 2 Diabetes 收起 << | Phase 1 | Terminated(IDMC recommendation... 展开 >> for safety concerns) 收起 << | - | - |
| NCT01598363 | Healthy Volunteers | Phase 1 | Completed | - | United States, Wisconsin ... 展开 >> Spaulding Clinical Research, LLC West Bend, Wisconsin, United States, 53095 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.03mL 0.41mL 0.20mL |
10.17mL 2.03mL 1.02mL |
20.34mL 4.07mL 2.03mL |
| 参考文献 |
|---|